Kokoschka E M
Wien Klin Wochenschr. 1978 Dec 22;90(24):870-4.
Effective therapy of malignant melanoma is still problematic. A variety of chemotherapeutic agents has proved to be ineffective in this tumour. The most extensively used chemotherapeutic agent for treatment of melanoma is DTIC (dimethyl-triaceno-imidazol-carboxamide). The objective response rate in monotherapy schedules has been reported to be up to 25%. Combination therapy with other cytostatic agents did not improve the results of DTIC alone. Experimental studies and clinical investigations have demonstrated that chemotherapy can be combined successfully with immunotherapy by potentiating the effect of tumour elimination. A review of the clinical studies with DTIC in malignant melanoma is presented.
恶性黑色素瘤的有效治疗仍然存在问题。已证明多种化疗药物对这种肿瘤无效。治疗黑色素瘤最广泛使用的化疗药物是达卡巴嗪（二甲基三氮烯咪唑甲酰胺）。据报道，单一疗法的客观缓解率高达25%。与其他细胞抑制剂联合治疗并未改善单纯使用达卡巴嗪的效果。实验研究和临床调查表明，化疗可通过增强肿瘤清除效果与免疫疗法成功联合。本文对达卡巴嗪治疗恶性黑色素瘤的临床研究进行了综述。
